The movie Extraordinary Measures tells the story of parents who formed a biotechnology company to develop a drug that could save the lives of children who have the rare life-threatening disease known as Pompe.
In the movie, which is based on the book The Cure, Harrison Ford plays research scientist Robert Stonehill, who was instrumental in finding the cure, while Brendan Fraser plays John Crowley, the man who raised US$100 million to buck the medical establishment.
In reality, John Crowley is the name of the person who started the biomedical company, but the real Dr Stonehill who developed the cure is in fact Chen Yuan-tsong (陳垣崇), director of Academia Sinica’s Institute of Biomedical Sciences.
PHOTO: CNA
At an event held earlier this week by the Taiwan Foundation for Rare Disorders to mark the debut in Taiwan of the movie’s DVD, Chen said he had mixed feelings watching the movie.
He said he began researching a cure for Pompe disease in 1991 after being saddened by the deaths of so many children from the affliction.
“Before I knew it, it had been 15 years,” he said. “It also surprised me that Hollywood would have made a motion picture out of it, making it the second movie about rare diseases and patients after Lorenzo’s Oil.”
Movie critic Roger Ebert said that Harrison Ford, as the film’s executive producer, probably saw Stonehill as a good role for himself and ordered a rewrite of the script because he could not play Chen.
Regardless of how Hollywood decided to recast Chen, his contribution to helping find the cure is well established.
He developed the treatment with colleagues at the Duke University Medical Center. His research and development was mostly done in the US, but Chen conducted his clinical trials for the cure — later named Myozyme — at National Taiwan University Hospital.
Myozyme, which took Chen and his team 15 years to research and develop, was introduced in Taiwan by US pharmaceutical company Genzyme and has been covered by the National Health Insurance (NHI) program since 2005, the foundation said.
Myozyme was sold in Europe and the US after it was approved by the US Food and Drug Administration and the EU health authority in 2006. It has contributed to saving the lives of more than 1,000 patients with Pompe disease, or acid maltase deficiency, worldwide each year, including 34 in Taiwan.
Young Pompe disease sufferers have symptoms similar to muscular dystrophy, the foundation said.
Without a cure, most children with Pompe disease die before they reach two years old. There is also a juvenile and adult form of the disease, which can appear at almost any age, the foundation said.
Currently, Pompe disease patients in Taiwan receive NT$7.9 million (US$245,577) per patient per year in Myozyme and related medical care under the NHI program, greatly reducing their families’ financial burden, the foundation said.
The foundation quoted tallies from the Cabinet-level Department of Health as indicating that there are nearly 6,000 families with rare disease patients in Taiwan, but more than 70 percent of them do not receive effective drugs or therapies, the foundation said.
‘DENIAL DEFENSE’: The US would increase its military presence with uncrewed ships, and submarines, while boosting defense in the Indo-Pacific, a Pete Hegseth memo said The US is reorienting its military strategy to focus primarily on deterring a potential Chinese invasion of Taiwan, a memo signed by US Secretary of Defense Pete Hegseth showed. The memo also called on Taiwan to increase its defense spending. The document, known as the “Interim National Defense Strategic Guidance,” was distributed this month and detailed the national defense plans of US President Donald Trump’s administration, an article in the Washington Post said on Saturday. It outlines how the US can prepare for a potential war with China and defend itself from threats in the “near abroad,” including Greenland and the Panama
The High Prosecutors’ Office yesterday withdrew an appeal against the acquittal of a former bank manager 22 years after his death, marking Taiwan’s first instance of prosecutors rendering posthumous justice to a wrongfully convicted defendant. Chu Ching-en (諸慶恩) — formerly a manager at the Taipei branch of BNP Paribas — was in 1999 accused by Weng Mao-chung (翁茂鍾), then-president of Chia Her Industrial Co, of forging a request for a fixed deposit of US$10 million by I-Hwa Industrial Co, a subsidiary of Chia Her, which was used as collateral. Chu was ruled not guilty in the first trial, but was found guilty
A wild live dugong was found in Taiwan for the first time in 88 years, after it was accidentally caught by a fisher’s net on Tuesday in Yilan County’s Fenniaolin (粉鳥林). This is the first sighting of the species in Taiwan since 1937, having already been considered “extinct” in the country and considered as “vulnerable” by the International Union for Conservation of Nature. A fisher surnamed Chen (陳) went to Fenniaolin to collect the fish in his netting, but instead caught a 3m long, 500kg dugong. The fisher released the animal back into the wild, not realizing it was an endangered species at
DEADLOCK: As the commission is unable to forum a quorum to review license renewal applications, the channel operators are not at fault and can air past their license date The National Communications Commission (NCC) yesterday said that the Public Television Service (PTS) and 36 other television and radio broadcasters could continue airing, despite the commission’s inability to meet a quorum to review their license renewal applications. The licenses of PTS and the other channels are set to expire between this month and June. The National Communications Commission Organization Act (國家通訊傳播委員會組織法) stipulates that the commission must meet the mandated quorum of four to hold a valid meeting. The seven-member commission currently has only three commissioners. “We have informed the channel operators of the progress we have made in reviewing their license renewal applications, and